Israeli-French drug development company Novagali SA, which was founded on the basis of research conducted by Prof. Simon Benita of the Hebrew University of Jerusalem, has successfully completed European Medicines Agency (EMEA) Phase III clinical trials of its eye treatment for Vernal Keratoconjunctivitis (VKC)..
This is a rare form of chronic allergic conjunctivitis seen in children and characterized by ocular discomfort, pain, itching and intense photophobia (sensitivity to light), which severely debilitates the patients.
The drug has been classified by the EMEA as an orphan drug. The company said that it would file for European Marketing Authorization by mid-2007.
Novagali has several eye treatments undergoing advanced clinical trials. Its next product will be designed to treat Dry Eye Syndrome.
Link [www.globes.co.il/serveen/globes/docview.asp?did=1000199856&fid=942]
Filed under Eye Treatment | Tags: eye | Comment Below
Related?
Phase II Clinical Trial of Mifepristone an Eye Drop Treatment for Steroid Associated Elevated Intraocular PressureSeptember 27th, 2006 Global bio-nanotech company pSivida Limited (NASDAQ:PSDV) (ASX:PSD) (Xetra:PSI) today announced the initiation of a Phase II clinical trial of Mifepristone (otherwise known as RU486) as an eye drop treatment for steroid associated elevated intraocular pressure (IOP). The investigator-sponsored trial will involve up to 45 patients in the United States.
Phase-II Clinical Trial of Drug Evizon for Wet Age-Related Macular DegenerationJune 28th, 2006 Biopharmaceutical company Genaera Corporation has commenced a multi-center phase II clinical trial to explore the efficacy and safety of higher doses of its investigational drug Evizon for the treatment of the eye disease, wet age-related macular degeneration. The study is designed to evaluate up to 140 patients with wet age-related macular degeneration (AMD) treated with Evizon at four dose levels of 40mg, 80mg, 120mg and 160mg over a 20 week period.
Dry age-related macular degeneration (AMD) can be treated by Acucela's visual cycle modulator ACU-4429June 24th, 2009 Acucela Inc. is a clinical-stage biotechnology company, presently focusing on visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide.
VEGF Trap-Eye Phase 2 trial reports significant improvement in neovascular diseaseSeptember 30th, 2008 Regeneron Pharmaceuticals, Inc and Bayer HealthCare AG has announced the result of Phase 2 trial of the VEGF Trap-Eye. It reported to have achieved durable improvements in visual acuity and in biologic measures of neovascular disease, including retinal thickness and active choroidal neovascularization lesion size.
Preliminary analysis of Xibrom QD announced to be satisfyingDecember 5th, 2008 ISTA Pharmaceuticals Inc. announced the preliminary analysis of a late-stage trial in Xibrom QD.
Can-Fite Begins Phase II Trials for Treatment of Symptoms of Keratitis Sicca (Dry-Eye Syndrome)January 31st, 2007 Can-Fite BioPharma Ltd. (TASE:CFBI) has begun Phase II clinical trials for its CF101 drug for the treatment of symptoms of keratitis sicca (dry-eye syndrome).
Chennai records rare form of eye disease September 13th, 2008 A Chennai hospital has detected a rare form of eye disease called microsporidial keratoconjunctivitis. The disease can make a patient blind, if untreated.
Viral conjunctivitis treatment - Alcon goes into phase II trialJuly 8th, 2009 Alcon in association with NovaBay has launched its treatment for Viral Conjunctivitis in the phase II trial. What is Viral Conjunctivitis?
Viruses are a common cause of conjunctivitis in patients of all ages.
